RxDoctor Payments Data

John Castaneda, MD

Family Medicine · Hebron, KYNPI 1467416628

Payments from drug & device makers

$5,462in general payments, 2019–2025

Across 329 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$892
  • Lilly USA, LLC$409
  • AstraZeneca$395
  • Amgen$299
  • Boehringer Ingelheim$257
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,35998%
  • Education$1032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,462 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$40,187
Medicare patients
152
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$91,100
TrulicityDulaglutide37$57,001
FarxigaDapagliflozin Propanediol34$42,528
EliquisApixaban60$41,093
JardianceEmpagliflozin24$32,806
MounjaroTirzepatide17$23,591
JanuviaSitagliptin Phosphate21$19,754
VraylarCariprazine Hcl11$15,656
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$12,630
LinzessLinaclotide14$10,703
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,010
Albuterol Sulfate HfaAlbuterol Sulfate101$3,142
Atorvastatin Calcium386$2,198
Varenicline Tartrate11$1,984
Levothyroxine Sodium213$1,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$892$91,10040 claims
Lilly USA, LLCTrulicity, Mounjaro$409$80,59254 claims
AstraZenecaFarxiga, Breztri Aerosphere$395$55,15948 claims
PfizerEliquis$194$41,09360 claims
Boehringer IngelheimJardiance$257$32,80624 claims
AbbVieVraylar, Linzess, Synthroid$1,040$26,93447 claims
MerckJanuvia$28$19,75421 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$124$10,01012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Hebron

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →